Skip to main content
Device/Product name
Active Ingredient
Date of decision
Submission type
New biological entity
ATC codes
Approved for provisional registration
What was the decision based on
The decision was based on quality (chemistry and manufacturing), nonclinical (pharmacology and toxicology), clinical (pharmacology, safety and efficacy) and risk management plan information submitted by the sponsor. The benefit-risk profile of Libtayo was considered favourable for the therapeutic use approved.
What steps were involved in the decision process

Registration timeline

The following table summarises the key steps and dates for this application.

Description Date
Designation (Provisional) 16 July 2019
Submission dossier accepted and first round evaluation commenced 30 August 2019
First round evaluation completed 31 January 2020
Sponsor provides responses on questions raised in first round evaluation 2 March 2020
Second round evaluation completed 9 April 2020
Delegate's overall benefit-risk assessment 19 June 2020
Sponsor's pre-Advisory Committee response Not applicable
Advisory Committee meeting Not applicable
Registration decision (Outcome) 2 July 2020
Completion of administrative activities and registration on ARTG 17 July 2020
Number of working days from submission dossier acceptance to registration decision* 195

*Statutory timeframe for standard applications is 255 working days

Date of entry onto ARTG
Original publication date
Black triangle scheme
Yes. As a provisionally registered product, this medicine will remain in the Black Triangle Scheme for the duration of its provisional registration
Dose forms
Concentrate for solution for infusion
350 mg/7 mL
Other ingredients

Histidine, histidine monohydrochloride monohydrate, sucrose, proline, polysorbate 80, water for injections

Pack sizes
Routes of administration
Intravenous infusion

Treatment must be initiated and supervised by physicians experienced in the treatment of cancer.

Recommended dose

The recommended dose is 350 mg cemiplimab every 3 weeks (Q3W) administered as an intravenous infusion over 30 minutes. Treatment may be continued until disease progression or unacceptable toxicity.

For further information refer to the Product Information.

Pregnancy category
DDrugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.The use of any medicine during pregnancy requires careful consideration of both risks and benefits by the treating health professional. This must not be used as the sole basis of decision making in the use of medicines during pregnancy. The TGA does not provide advice on the use of medicines in pregnancy for specific cases. More information is available from obstetric drug information services in your State or Territory.
What was approved

Libtayo (cemiplimab) was provisionally approved for the following therapeutic use:

Libtayo as monotherapy has provisional approval in Australia for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.

The decision to approve this indication has been made on the basis of objective response rate (ORR) and duration of response from single arm clinical studies. The sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

The provisional registration period for the above medicine is two years starting on the day specified in the ARTG certificate of registration.

What is this medicine and how does it work
Cemiplimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with its ligands programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). Engagement of PD-1 with its ligands PD-L1 and PD-L2, which are expressed by antigen presenting cells and may be expressed by tumour cells and/or other cells in the tumour microenvironment, results in inhibition of T cell function such as proliferation, cytokine secretion, and cytotoxic activity. Cemiplimab potentiates T cell responses, including antitumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands.
What post-market commitments will the sponsor undertake
  • Libtayo (cemiplimab) is to be included in the Black Triangle Scheme. The Product Information and Consumer Medicines Information for Libtayo must include the black triangle symbol and mandatory accompanying text for the products entire period of provisional registration.
  • Confirmatory trial data (as identified in the sponsor's plan to submit comprehensive clinical data on the safety and efficacy of the medicine before the end of the 6 years that would start on the day that registration would commence) must be provided.

    Specifically, the sponsor must conduct studies as described in the clinical study plan in version 1.1 (date 28 February 2020) of the Australian specific Annex. The following study report(s) should be submitted to the TGA:

    • Study R2810-ONC-1540, by 31 October 2022
    • Study R2810-ONC-1540 (Group 6), by 31 March 2023

    Further guidance for sponsors is available on the TGA website.

  • Batch release testing and compliance with Certified Product Details (CPD)
    • It is a condition of registration that all batches of Libtayo (cemiplimab) imported into/manufactured in Australia must comply with the product details and specifications approved during evaluation and detailed in the CPD.
    • It is a condition of registration that each batch of Libtayo (cemiplimab) imported into/manufactured in Australia is not released for sale until samples and/or the manufacturer's release data have been assessed and endorsed for release by the TGA Laboratories Branch. Outcomes of laboratory testing are published biannually in the TGA Database of Laboratory Testing Results.
    • The sponsor should be prepared to provide samples, reference materials and documentary evidence as defined by the TGA Laboratories branch. The sponsor must contact for specific material requirements related to the batch release testing/assessment of the product. More information is available at Testing of biological medicines

      This batch release condition will be reviewed and may be modified on the basis of actual batch quality and consistency. This condition remains in place until the sponsor is notified in writing of any variation.

  • Certified Product Details

    The CPD, as described in Guidance 7: Certified Product Details of the Australian Regulatory Guidelines for Prescription Medicines (ARGPM), in PDF format, for the above products should be provided upon registration of these therapeutic goods. In addition, an updated CPD should be provided when changes to finished product specifications and test methods are approved in a Category 3 application or notified through a self-assessable change.

  • The Libtayo European Union-risk management plan (EU-RMP) (version 1.0, dated 26 April 2019, data lock point 10 October 2018), with Australian specific Annex (version 1.1, dated 28 February 2020), included with submission PM-2019-03270-1-4, and any subsequent revisions, as agreed with the TGA will be implemented in Australia.

    An obligatory component of risk management plans is routine pharmacovigilance. Routine pharmacovigilance includes the submission of periodic safety update reports (PSURs). Reports are to be provided in line with the current published list of EU reference dates and frequency of submission of PSURs until the period covered by such reports is not less than three years from the date of the approval letter.

    The reports are to at least meet the requirements for PSURs as described in the European Medicines Agency's Guideline on Good Pharmacovigilance Practices (GVP) Module VII-periodic safety update report (Rev 1), Part VII.B Structures and processes.

    Note that submission of a PSUR does not constitute an application to vary the registration.

  • For all injectable products the Product Information must be included with the product as a package insert.

Help us improve the Therapeutic Goods Administration site